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Introduction
he latest statistics from the National Cancer Institute estimates 
that 72,570 new cases of bladder cancer will be diagnosed in the United 
States in 2013 and will result in 15,210 deaths. Bladder cancer is six 
times more prevalent in developed countries than in under developed 
countries and is the ith most common human malignancy. Bladder 
cancer is also one of the most expensive cancers to treat since the 
course of therapy requires extensive patient surveillance to monitor for 
recurrence as well as repeated procedures to remove new tumors or 
cryptic tumor foci overlooked during the initial transurethral resection 
[1-4]. hese urothelial carcinomas are primarily of epithelial origin 
(>90%) with multiple genetic pathways leading to disease progression 
[5]. Patients with high-risk non-muscle invasive bladder cancer 
receive adjuvant Bacillus Calmette-Guérin (BCG) therapy alone or in 
combination with interferon α-2b [6], radiation and/or chemotherapy, 
typically methotrexate, vinblastine, doxorubicin and cisplatin (MVAC), 
or other targeted strategies [7]. Even with the latest pharmacologic 
strategies, the relative survival rate for bladder cancer is 5 years, while 
the median survival for patients with inoperable metastatic bladder 
cancer is 7 to 20 months [5,8,9]. 
A new paradigm in cancer therapy is slowly gaining popularity 
and continues to evolve from the work of Roger Daoust and Henryk 
Taper [10-13]. Daoust studied the DNase I and DNase II expression 
patterns of a variety of tumor types and discovered that DNases were 
oten suppressed in tumor cells, despite being active in the surrounding 
tissues and vasculature. Daoust also found that reactivation of both 
DNases was associated with successful cancer treatment or spontaneous 
cancer remission. his work was extended by Henryk Taper and co-
workers [14,15] for the treatment of liver and other cancers by using 
a combination of vitamin C and vitamin K
3
 (VC:VK
3
) in a 100:1 ratio. 
Taper showed that vitamin C reactivated DNase II, while vitamin 
K
3
 reactivated DNase I with the combination synergistically causing 
tumor cell death. Further experimentation showed that VC:VK
3
 was 
an efective chemo- and radio-sensitizer [11-13]. Subsequently, these 
studies were extended to include bladder and [16-22] other cancers 
[23-27]. 
Unlike the majority of chemotherapeutic agents which target 
rapidly dividing cells, VC:VK
3
 appears to target tumor cells by 
inlammation [23]. Inlammation is regarded as a “secret killer” and 
is present in the microenvironment of most neoplastic tissues [28]. A 
wide variety of stimuli including: microbial infections, viral infections 
and autoimmune disease can trigger chronic inlammation and the 
subsequent development of cancer [29]. Chemokine and cytokine 
production orchestrated by inlammation-sensitive transcription 
factors are the key players in this cancer-related inlammation (CRI) 
[30-32] and its role in tumor initiation, promotion, invasion, and 
metastasis [33]. herefore, inlammation can be considered an enabling 
characteristic for the acquisition of the core properties of cancer 
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Abstract
Introduction: Vitamin C (VC), Vitamin K
3
 (VK
3
) and the combination (VC:VK
3
) were evaluated against human 
bladder cancer cell lines RT-4 and T24 to evaluate their synergistic anticancer activity. 
Methods/Results: An MTT assay compared a 1hr pulsed versus a 5hr continuous exposure. VC:VK
3
 was 
synergistic, increasing the antitumor activity 12- to 24 fold for RT-4 cells. VC:VK
3
 pulsed versus continuous exposure 
produced comparable CD
50
 values, indicating a triggered response involving a catalase reversible redox mechanism 
generating hydrogen peroxide. Hydrogen peroxide production caused lipid peroxidation and depletion of cellular 
thiols. ATP levels were measured over 5hrs to determine metabolic effects where VC:VK
3
 caused a unique spike 
in ATP levels. Though the cause of the ATP spike is unknown a possible mechanism is a shunt formed around a 
defective region of complex III of the ETC from coenzyme Q to cytochrome c, producing a shift from glycolytic to 
oxidative metabolism and a diminution of lactic acidosis. Analysis of mitochondrial and extra mitochondrial calcium 
levels revealed a unique calcium pattern for RT4 cells treated with CD
90
 doses of VC, VK
3
 or VC:VK
3
. 
Conclusion: VC:VK
3
 was able to cause autoschizic cell death through oxidative stress, thiol depletion, lipid 
peroxidation, modiication of ATP levels and calcium regulation. Because of these results, VC:VK
3
 was granted 
orphan drug status for the treatment of metastatic or locally advanced, inoperable transitional cell carcinoma of 
the urothelium (stage III and IV bladder cancer). Efforts are underway to conduct a phase II clinical trial for this 
indication.
Vitamin C and K3 Combination Causes Enhanced Anticancer Activity against RT-4 Bladder Cancer Cells
Karen McGuire1, James Jamison1*, Jacques Gilloteaux2 and Jack L. Summers1
1The Apatone Development Center, St. Thomas Hospital, Summa Health System, USA
2Department of Anatomical Sciences, St Georges’ University International School of Medicine, K B Taylor Scholar’s Programme, Newcastle upon Tyne, UK
Citation: McGuire K, Jamison J, Gilloteaux J, Summers JL (2013) Vitamin C and K
3
 Combination Causes Enhanced Anticancer Activity against 
RT-4 Bladder Cancer Cells. J Cancer Sci Ther 5: 325-333. doi:10.4172/1948-5956.1000223
Volume 5(10) 325-333 (2013) - 326 
J Cancer Sci Ther 
ISSN: 1948-5956 JCST, an open access journal
[28]. Furthermore, because smoldering inlammation in the tumor 
microenvironment inluences responses to chemotherapy as well as 
hormonal therapy and is involved in the pathogenesis of many types of 
cancer including bladder cancer, CRI represents a target for therapeutic 
intervention [28,34]. For example, tumor cells possess a greater need for 
glucose than normal cells and express facilitative glucose transporters 
(GLUTs) to achieve this task. Because of the structural resemblance of 
dehydroascorbic acid (DHA, the oxidized form of vitamin C) to glucose, 
DHA can also enter the tumor cells through the GLUT transporters 
and bioaccumulate. Epithelial tumors appear to rely on superoxide 
(inlammation) which is produced constitutively via NADPH oxidase 
of non-neoplastic stromal cells to oxidize the ascorbic acid to DHA 
[35]. Once dehydroascorbic acid enters the cells, it is reduced and 
retained as ascorbic acid (AA) which is not transportable through the 
bidirectional GLUTs [36]. Subsequently, AA, DHA or their metabolites 
inhibit many cellular processes, including glycolysis [37]. Because of 
the Warburg efect during which cancer cell metabolism becomes more 
reliant on glycolysis than mitochondrial oxidative respiration, the 
VC:VK
3
 combination is able to exploit both inlammation and tumor 
metabolism in a in a multi-pronged strategy against a variety of tumor 
cells, including RT4 cells, that results in a new type of cell death termed 
autoschizis [17,20,26,27]. hese results have been extended into the 
clinical setting with a phase I/IIa clinical trial for end stage prostate 
cancer which demonstrated both safety and eicacy [38]. he results 
presented here represent an initial investigation into the mechanism(s) 
responsible for autoschizic cell death in grade I bladder cancer (RT-4) 
cells following VC:VK
3
 treatment.
Materials and Methods
Cell lines
Grade I (RT-4) and grade III/IV (T24) human bladder cancer cell 
lines were purchased from the American Type Culture Collection 
(Rockville, MD, U.S.A.) and were grown in Eagle’s minimum essential 
medium(MEM) and McCoy’s 5A respectively (Gibco, Grand Island, 
NY, U.S.A.). All media was supplemented with 10% fetal bovine serum 
(Gibco) and 50 µg/mL Gentamycin sulfate (Sigma Aldrich, St. Louis, 
MO).
Test solutions
Sodium L-Ascorbate (VC) and menadione sodium bisulite (VK
3
) 
were purchased from Sigma Chemical Company (St Louis, MO, 
U.S.A.) and were dissolved in 1X phosphate-bufered saline (PBS). For 
the cytotoxicity assay vitamins were diluted to a inal concentration 
of  10,000 µm VC and 500 µM VK
3
 alone and the combination was 
diluted to a inal concentration of 8,000 µM VC and 80 µM VK
3 
respectively. Two fold serially dilutions were then performed and 
solutions were added to the plate. he CD
90
 concentrations determined 
by the cytotoxicity assay [VC (8,750 µM), VK
3 
(90 µM) and VC:VK
3 
(520 µM:5.2 µM)] were used for all additional experiments. 
Protein concentration assay
Total protein content for each sample was determined using the 
method of Bradford [39] and sham treated cells served as control for 
all experiments. 
Cytotoxicity assay
Tumor-cell cytotoxicity was performed using the microtetrazolium 
assay [MTT, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-
diphenyltetrazolium bromide] as described previously [16]. Briely, 
corning 96-well titer plates were seeded with tumor cells (5 x 103 per well) 
and allowed to grow and spread overnight. Cells were consequentially 
incubated for 1-h or 5-days with VC or VK
3
 alone or in combination. 
Formazan crystals were dissolved in DMSO and plates were read at 
590nm and 620nm on a Biotek Synergy HT plate reader. he CD
50
 
was determined based on the line of best it. he fractional inhibitory 
concentration index (FIC) was employed to evaluate synergism.
Analysis of protein thiols
hiol levels were determined according to Nagelkerke et al. [40]. In 
brief, RT4 cells were treated with CD
90
 concentrations of the vitamins 
alone or in combination. Cells were washed with PBS, culture media 
and trypsinized every hour up to 6 hrs. Cells were subsequently pelleted 
for 5 min at 1000 rpm, washed twice with 6.5% TCA (trichloroacetic 
acid) and resuspended in 1 mL of 0.5 M Tris-HCl (pH 7.6). To detect 
thiols 50 µL of 10 mM methanolic Ellman’s Reagent was added to each 
sample and incubated for 20 min at room temperature. he solution 
was then centrifuged for 5 min at 1000 rpm and the absorbance of 
the resulting supernatant was measured at 412 nm. hiol content was 
determined based on a reduced glutathione (GSH) standard curve and 
was expressed as µM thiols per mg of protein. 
Analysis of ATP
RT4 cells were seeded at a density of 1.0 x 106 and allowed to 
grow and spread overnight at 37ºC and 5% CO
2
. Culture medium was 
removed; the cells were treated with vitamins alone or in combination 
and ATP content were determined every hour for 5 hrs. Cells were then 
washed with 1xPBS covered with vitamin-free media and solubilized in 
somatic cell ATP releasing reagent (Sigma Chemical Co, St Louis, MO). 
Cellular ATP content was determined using an ATP bioluminescent 
assay kit (Sigma, St. Louis, MO) [41] and bioluminescence was then 
measured using a Beckman LS 9000 scintillation counter set for single 
photon counting. ATP content was then calculated based on an ATP 
standard curve and was expressed as nM ATP per mg of protein.
Lipid peroxidation
Lipid peroxidation was evaluated using the thiobarbituric acid 
(TBA) method [42]. RT4 cells were treated and harvested as described 
in the thiol assay. Ater centrifugation, the cell pellets were resuspended 
in 6.0% TCA (trichloroacetic acid), mixed with 1 ml of 0.25 N HCl 
containing 0.375% TBA and 15% TCA heated in a water bath for 15 
min at 95ºC and then allowed to cool. Following centrifugation the 
supernatant was monitored luorimetrically for malondialdehyde 
(MDA) production using an excitation wavelength of 532 nm and 
an emission wavelength of 555 nm. Data was expressed as nM MDA 
per mg of protein, calculated on the basis of an MDA standard curve 
generated using 1, 1, 3, 3-tetramethoxypropane.
Calcium
Calcium was assayed according to the method of Scott et al. [43]. 
Briely, 4x106 cells were suspended in 1mL of calcium and magnesium 
free HBSS containing CD
90
 vitamin concentrations and incubated at 
37˚C for 15, 30, 45 and 60 min. Following incubation the cell suspension 
was treated with 100 µL of 390 µM arsenazo III (2,2’-[1,8-dihydroxy-
3,6-disulpho-2,7-naphthalene-bis(azo)]-dibenzenearsonic acid). 
Followed by the addition of 100 µL of 130 µM FCCP (carbonyl cyanide 
p-(triluromethoxy) phenylhydrazone) to the cell suspension and the 
mitochondrial calcium release was recorded until no further change 
in absorbance was observed at 675-685 nm using a HP8451A diode 
array spectrophotometer. hen 100 µL of 195 mM A23187 (a calcium 
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ionophore) was added and extra mitochondrial calcium release was 
recorded until no further change in absorbance was recorded at 675-685 
nm. Calcium concentration was determined using a calcium standard 
curve. he linear range of the standard curve was used to express the 
calcium concentration as nM calcium/mg protein [44].
Statistics
A three-way ANOVA was performed using BMDP statistical 
sotware. In the three-way ANOVA, the two-way interactions were 
tested at the 0.005 level of signiicance. All other efects were tested at 
the 0.0022 level of signiicance.
Results
VC, VK
3 
and the combination of VC:VK
3
 in a ratio of 100:1 have 
been evaluated for their cytotoxicity against both the low grade (RT-4) 
and high grade (T-24) bladder cancer cell lines following continuous 
5-day vitamin exposure or 1-h vitamin exposure followed by a 5-day 
incubation in media (Table 1). A continuous 5-day vitamin treatment 
of the RT-4 cells resulted in CD
50 
values of 2,430 µM for VC, 12.8 µM for 
VK
3
 and 110 µM:1.10 µM for the VC:VK
3
 combination. hese results 
represented a 22-fold decrease of the CD
50
 of VC and a 12-fold decrease 
in the CD
50
 of the VK
3
. he fractional inhibitory concentration index 
(FIC) was used to assess the synergism of the combination. For the 
RT-4 cells, the VC:VK
3
 resulted in an FIC value of 0.136. Continuous 
5-day vitamin treatment of the T24 cells produced a CD
50
 value of 1,490 
µM for VC, 13.1 µM for VK
3
 and 212 µM: 2.13 µM for VC:VK
3
. hese 
results correspond to a 41-fold decrease of the CD
50
 of VC and a 6-fold 
decrease in the CD
50
 of the VK
3
 with an FIC value of 0.158 (Table 1).
Studies by Taper and co-workers [11] demonstrate that exposure 
to the combination for as little as 1h, results in signiicant anti-tumor 
activity. A similar experiment was performed to determine if this efect 
was repeatable against RT-4 and T24 cells following a 1hr vitamin 
exposure. A 1-h vitamin treatment of the RT-4 cells resulted in CD
50
 
values of 4,740 µM for VC, 60.7 µM for VK
3
 and 267 µM:2.68 µM for 
VC:VK
3
. hese values correspond to an 18- fold decrease in the CD
50
 
value of VC, a 22-fold decrease in the CD
50
 value of VK
3
 and produced 
an FIC value of 0.100. In the case of the T24 cells, the CD
50 
values were 
4,970 μM for VC, 73.2 µM for VK
3
 and 120 µM: 1.21 µM for VC:VK
3.
. 
hese values correspond to a 41-fold decrease in the CD
50
 of VC and a 
59-fold decrease in the CD
50
 of the VK
3
 with a corresponding FIC for 
the vitamin combination of 0.093 (Table 1). 
VC, VK
3
 or the VC:VK
3
 combination has been shown to generate 
hydrogen peroxide (H
2
O
2
) and other reactive oxygen species (ROS) 
in tumor cells and these species may initiate peroxidation of lipid 
membranes [15,17]. Vitamin induced lipid peroxidation (Figure 1) was 
examined using the thiobarbituric acid method. he lipid peroxidation 
of sham-treated RT-4 cells displayed an average value of 3.17nM 
(MDA)/mg of protein. However, this is only a measure of the lipid 
peroxidation that occurs during the heating of samples to 95 ºC during 
the assay and can, therefore, be considered as a baseline for MDA 
production. VC treatment resulted in MDA peak at 4.27 nM/mg with 
an average value of 3.67 nM/mg. Lipid peroxidation of VK
3
-treated 
cells was 4.34 nM/mg at 1 h increased to near 5.84 nM/mg by hours 
3 and 4 and decreased to 4.27 by hour 5. he average VK
3
-induced 
lipid peroxidation was 4.98 nM/mg. his spike in lipid peroxidation 
was attributed to a concomitant increase in ROS production due to 
redox cycling and a decrease in catalase activity [45]. VC:VK
3,
 lipid 
peroxidation peaked at 6.7 nM/mg with an average value of 5.58 nM/
mg of protein. Overall, the VC:VK
3 
treatment resulted in a statistically 
signiicant alteration in lipid peroxidation (p<< 0.0022) for all time 
points compared to control. 
Administration of VK
3
 or menadione has been shown to cause 
depletion of GSH and oxidation of protein sulphydryl groups in 
cytoskeletal proteins [46,47]. herefore, the efect of vitamin treatment 
on cellular thiols has been examined (Figure 2). he sham-treated RT4 
cells presented with an average thiol content of 1.39 ± 0.42 µM thiol/
mg of protein. All other cells were exposed to the vitamins for 1 h and 
then incubated in vitamin-free culture media for 5 h. VC treatment 
in the irst hour depleted thiol levels to 0.92 ± 0.31 µM thiol/mg of 
protein which was not statistically signiicant compared to the control 
value at 1 h. hiol levels remained constant during the second hour and 
dropped steeply to 0.47 ± 0.03 µM thiol/mg of protein during the third 
hour. hese levels rebounded to 0.73 ± 0.12 µM thiol/mg of protein 
during the fourth hour and then returned to second and third hour 
levels of 0.45 ± 0.03 µM thiol/mg of protein during the inal hour. he 
values for the remaining hours are statistically signiicant (p << 0.0022) 
compared to their corresponding control values.
VK
3
 treatment decreased thiol levels to 0.62 ± 0.5 µM thiol/mg of 
protein during the irst hour, where they remained constant for the 
next three hours. By ive hours thiol levels lowered slightly to 0.54 
± 0.1 µM thiol/mg of protein. he VC:VK
3 
combination produced a 
stepped decrease in thiol levels during the irst and second hour from 
0.63 ± 0.05 µM thiol/mg to 0.45 ± 0.03 µM thiol/mg of protein. Overall, 
VC:VK
3
 treated cells induced a signiicant (p<0.0022) depletion of 
cellular thiols.
Investigation using transmission electron microscopy has shown 
that mitochondrial ultrastructure is altered by vitamin treatment 
resulting in autoschizic cell death [15,48]. To determine the role of 
mitochondria in VC:VK
3
 induced cell death the intracellular levels of 
ATP were measured over the course of 5hrs to look for an ATP-less cell 
death as a result of mitochondrial damage (Figure 3). he ATP content 
of sham treated RT-4 cells varies from 58.10 to 62.20 nM ATP/mg of 
protein with an average value of 59.64 ± 2.4 nM ATP/mg of protein. 
VC exposure results in an increase in ATP levels to 147 ± 8.64 nM 
during the irst hour. Subsequently, the ATP levels decreased to 86.0 
Cell Line Incubation Time
Vitamins Alone Vitamin Combination
FIC
VC
CD50
(µM)
VK
3
CD50
(µM)
VC
CD50
(µM)
VK
3
CD50
(µM)
RT4
1 h 4,740 ± 27.2 60.7 ± 4.01 267 ± 4.04 2.68 ± 0.05 0.100
5 days 2,430 ± 28.3 12.8 ± 0.03 110 ± 9.73 1.10 ± 0.10 0.136
T24
1 h 4,970 ± 27.4 73.2 ± 5.91 120 ± 7.0 1.21 ± 0.07 0.093
5 days 1,490 ± 141 13.1 ± 0.01 212 ± 7.6 2.13 ± 0.06 0.158
FIC = CD
50
A comb/ CD
50
A alone + CD
50
B comb/ CD
50
B alone, where CD
50
A alone and CD
50
B alone are 50% cytopathic doses of each vitamin alone; CD
50
A comb and CD
50
B comb are the 50% 
cytopathic doses of the vitamins administered together. FIC<1.0 is synergistic, FIC>1 is antagonistic and FIC=1 is indifferent
Table 1: Antitumor Activity of Vitamins Against RT-4 Bladder Carcinoma Cells.
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± 4.73 nM during the second hour and remained relatively constant 
during the third and fourth hours and then fell to 56.1 ± 4.09 nM 
during the inal hour. VK
3
 treatment lowered ATP levels to 39.9 ± 0.99 
nM during the irst hour. Subsequently, ATP levels rose slightly to 48.8 
± 4.52 nM during the second hour, remained relatively constant for the 
next 3 hours and increased to near control levels during the inal hour. 
he VC:VK
3
 combination produced a slight decrease in ATP 
concentration to 46.7 ± 2.13 nM during the irst hour. ATP levels 
increased during the second and third hours to 134 ± 1.46 nM and 
decreased gradually to near control levels during the inal two hours. 
hese results demonstrate that pulse treatment of RT-4 cells with VC 
alone or with the VC:VK
3
 combination resulted in a transient increase 
in intracellular ATP levels following vitamin treatment. he treatment 
of the cells with the VC:VK
3
 combination resulted in a signiicant (p 
<< 0.0022) alteration in ATP levels for all hours except for 5h when the 
diference from control is not signiicant.
To determine the role of calcium in VC:VK
3
 induced cell death the 
mitochondrial and extra mitochondrial calcium levels were measured 
during the irst 1hr to look for diferences in apoptotic and autoschizic 
calcium patterns (Figure 4 and 5). he mitochondrial calcium (Figure 
4) content of sham treated RT-4 cells varies from 7.11 to 7.95 nM 
calcium/mg of protein with an average value of 7.47 ± 0.63 nM calcium/
mg of protein. VC exposure results in a ~70% decrease in calcium levels 
to 2.32 ± 0.3 nM during the irst thirty minutes compared to control. 
Subsequently, by 45min to 1 hour the calcium levels rebound to ~50% 
of control values with an average of 3.67 ± 0.35 nM. VK
3
 treatment 
also lowered calcium levels by ~75% compared to control values to 1.66 
± 0.3 nM during the irst thirty minutes. Subsequently, by 45min to 
1 hour the calcium levels rebound to ~40% of control values with an 
average of 4.32 ± 0.3 nM by 1hr. 
Unlike VC and VK
3
 alone, the VC:VK
3
 combination showed no 
statistically signiicant change in mitochondrial calcium concentration 
during the irst thirty minutes with an average of 7.0 ± 0.25 nM. his lack 
of change in mitochondrial calcium concentration during the irst 30 
minutes probably relects a slower rate of mitochondrial accumulation 
Figure 1: RT-4 cells were treated with the vitamins at their CD
90 
doses VC 
(8,750µM), VK
3 
(90µM) and VC:VK
3 
(520µM:5.2µM) and harvested at one hour 
intervals for 5 h and assayed for lipid peroxidation using the thiobarbituric acid 
method. Malondialdehyde (MDA) production was monitored luorimetrically 
and data was expressed as nM MDA per mg of protein and calculated based 
on an MDA standard curve. Values are the mean ± standard error of the 
mean of three experiments with three readings per experiment and compared 
to the control. VC:VK
3
 treatments resulted in signiicant amounts of lipid 
peroxidation compared to control (P<<0.0022).
 
0
1
2
3
4
5
6
7
Control VC VK3 VC:VK3 
n
M
  M
D
A
/m
g
 P
ro
te
in
Vitamin-induced lipid peroxidation 
1
2
3
4
5
Figure 2: RT4 cells were treated for 1 hour with the vitamins at their CD
90
 
doses,(VC (8,750µM), VK
3 
(90µM) and VC:VK
3 
(520µM:5.2µM)) harvested 
at one hour intervals for 5 h and assayed for cellular thiol content by 
monitoring absorbance following reaction with Ellman’s Reagent. Data has 
been expressed as µM Thiol/mg of protein, calculated on the basis of a GSH 
standard curve. Values are the mean ± standard error of the mean of three 
experiments with three readings per experiment. VC:VK
3
 causes signiicant 
depletion of cellular thiols compared to the control (P<<0.0022).
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Figure 3: RT-4 cells were treated for 1 hour with the vitamins at their CD
90
 
doses (VC (8,750µM), VK
3 
(90µM) and VC:VK
3 
(520µM:5.2µM)) and then 
harvested at one hour intervals for 5 h. ATP content was assayed using a 
bioluminescence assay. Data has been expressed as nM ATP per mg of 
protein and calculated on the basis of an ATP standard curve. Values are the 
mean ± standard error of the mean of three experiments with three readings 
per experiment and were compared to the control (P<<0.0022 between 
VC:VK
3 
and control from 2-4 hrs). 
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Figure 4: RT-4 cells were exposed to vitamins 15, 30, 45 and 60 min their 
CD
90
 doses, (VC (8,750µM), VK
3 
(90µM) and VC:VK
3 
(520µM:5.2µM)) 
harvested and analyzed for mitochondrial calcium content. Calcium content 
was assayed using arsenazo III. Data has been expressed as nM Calcium 
per mg of protein calculated on the basis of a calcium standard curve. Values 
are the mean ± standard error of the mean of three experiments with three 
readings per experiment and were compared to the control (P<<0.0022 
between treatment and control for all groups by 45-60 minutes).
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of the VC and VK
3
 in the combination because their concentrations 
are 17-fold lower than that used in the vitamins alone. Subsequently, 
mitochondrial calcium levels slowly decrease to an average of 4.5 ± 
0.35 nM by 1hr never dropping below ~40% of control mitochondrial 
calcium levels. hese results demonstrate that treatment of RT-4 cells 
with VC or VK
3
 alone caused a transient release in mitochondrial 
calcium levels with levels subsequently rebounding to ~40-50% of the 
control value. he treatment of the cells with the VC:VK
3
 combination 
displayed a calcium pattern that was distinctly diferent from the 
mitochondrial calcium pattern created by either vitamin administered 
alone with, combination mitochondrial calcium levels never dropping 
below 40% of control levels. 
Changes in extra mitochondrial calcium were also examined to look 
for calcium release from other cellular compartments including the 
endoplasmic reticulum and cell membrane. he extra mitochondrial 
calcium content of sham treated RT-4 cells varies from 8.23 to 8.99 nM 
calcium/mg of protein with an average value of 8.63 ± 0.63 nM calcium/
mg of protein. VC exposure results in a ~80% decrease in calcium 
levels to 1.43 ± 0.2 nM during the irst thirty minutes compared to 
control. Subsequently, by 45min to 1 hour the calcium levels rebound 
to ~30-35% of control values with an average of 3.75 ± 0.45 nM. 
VK
3
 treatment also lowered calcium levels by ~55-60% compared to 
control values to an average of 3.75± 0.75 nM during the irst thirty 
minutes. Subsequently, by 45min the calcium levels plummet ~20% of 
control values with an average of 1.33± 0.6 nM. Finally, by 1hr extra 
mitochondrial calcium levels slightly rebound to ~30% of control but 
remain low. 
he VC:VK
3
 combination showed a maximum ~36% decrease in 
extra mitochondrial calcium concentration by thirty minutes with an 
average of 5.5 ± 0.2 nM. By 45 minutes to 1hr the extra mitochondrial 
calcium level slowly rises upward to reach ~75% of the control level. 
hese results demonstrate that treatment of RT-4 cells with VC or VK
3
 
alone caused a decrease in extra mitochondrial calcium levels while the 
combination displayed only a slight decrease in extra mitochondrial 
calcium over the course of 1hr. 
Discussion
VC is cytotoxic to a variety of tumor types [49-51] when 
administered as a monotherpy or as a sensitizer of tumor cells to 
radiation and chemotherapy [49,52,53]. At megadoses, VC generates 
hydrogen peroxide, ROS, depletes cellular thiols and initiates lipid 
peroxidation (LPO). One problem commonly associated with VC 
therapy is achieving and maintaining clinically active doses in the 
bloodstream. For example, following oral VC administration, VC 
concentrations in the blood peak at ~ 220 µM which is below the 
concentration required for clinical eicacy. Conversely, following 
intravenous (iv) VC administration, VC concentrations in the blood 
peak at ~ 885 µM which is suicient for clinical eicacy. However, 
the half-life of this iv dose of VC is short with circulating VC doses 
returning to control levels within 4 to 6 h [54]. his problem of 
achieving and maintaining clinically active doses in the bloodstream 
has hindered VC monotherapy from becoming a widely acceptable 
cancer therapy. 
VK
3
 also exhibits in vitro cytotoxic activity against a variety of 
tumor cell lines [55] as well as in vivo antitumor activity [56]. VK
3
 can 
act to detoxify ROS (reduced environment) or act as a ROS generator 
(prooxidant environment) through single electron (1e-) and two 
electron (2e-) cycling. At doses greater than 50 µM, VK3 causes tumor 
cell death [57] by depleting cellular pools of ADP, ATP and glutathione 
(GSH); inducing single stranded DNA breaks and oxidizing protein 
sulphydryl groups [50]. VK
3
 is also a chemosensitizer for most 
traditional chemotherapeutic agents [58]. he MTD for menadione 
was determined in phase I and II studies to be 2.5 g/m2, but once the 
dose was increased to between 4 and 8 g/m2 hemolysis occurred despite 
the presence of red blood cell glucose-6-phosphate dehydrogenase with 
no notable coagulopathy [59-61]. 
Combining VC and VK
3
 in a ratio of 100:1 lowered the CD
50
 values 
of VC and VK
3
 6 to 41 fold. his drop in CD
50
 values places the efective 
concentration of both VC and VK
3
 into a physiologically relevant 
range (Table 1). In addition, the combination is a more efective ROS 
generator than either of the constituents alone and targets tumor cells 
thus, avoiding indiscriminate redox damage. Finally, the VC:VK
3
 
combination is an efective chemotherapy and radiation sensitizer in 
hepatoma bearing mice [11-13]. Taper and his associates have shown 
that the VC:VK
3
 combination exhibited antitumor activity with 
exposure times as short as 1 h [11]. he results of previous studies with 
bladder cancer and other tumor cell lines demonstrated that VC:VK
3
 
induced cell death via a caspase independent process that was not 
apoptosis [27,62,63]. In addition, VC:VK
3
 treatment did not lead to 
the conversion of soluble LC3-I to autophagic vesicle associated LC3-II 
and thus tumor cell death was not due to autophagy [64-66]. Instead, 
cell death was due to autoschizis with cathepsins, not caspases, as the 
cell executioners [65,66]. In the case of RT4 cells, the antitumor activity 
of VC:VK
3
 was due to cell death by autoschizis [20]. Ultrastructural 
studies of vitamin-treated RT4 cells undergoing autoschizis revealed 
exaggerated membrane damage and an enucleation process in which 
the perikarya separated from the main cytoplasmic body by self-
excision. hese self-excisions continued until all that remained was an 
intact nucleus surrounded by a narrow rim of cytoplasm that contained 
damaged organelles. he nucleus exhibited nucleolar segregation 
and chromatin decondensation followed by nuclear karryohexis and 
karyolysis [20].
In previous studies, including those with RT4 cells, it was 
determined that H
2
O
2
 and other ROS were essential efectors of VC, 
VK
3
 and VC:VK
3
 activity [46,67] and the anti-cancer activity of the 
Figure 5: RT-4 cells were exposed to vitamins 15, 30, 45 and 60 min their CD
90
 
doses, (VC (8,750µM), VK
3 
(90µM) and VC:VK
3 
(520µM:5.2µM)) harvested 
and analyzed for extramitochondrial calcium content. Calcium content was 
assayed using arsenazo III. Data has been expressed as nM Calcium per mg 
of protein calculated on the basis of a calcium standard curve. Values are the 
mean ± standard error of the mean of three experiments with three readings 
per experiment and were compared to the control (P<<0.0022 between 
treatment and control for all groups over time). 
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vitamins could be destroyed by addition of exogenous catalase at 
doses as low as 100 µg/mL [68]. While VC generated H
2
O
2
 peroxide 
primarily outside of the cell and VK
3
 generated primarily intracellular 
H
2
O
2
, the VC:VK
3
 combination appeared to produce both extracellular 
and intracellular H
2
O
2
 with total H
2
O
2
 production being additive [45]. 
In addition, VC and VK
3
 formed a redox pair resulting in both one 
and two electron cycling and the depletion of cellular thiols as well as 
the generation of hydrogen peroxide, superoxide and other ROS [23]. 
he fact that a greater amount of catalase was required to destroy the 
antitumor activity of VK
3
 than was required to destroy the antitumor 
activity of the vitamin combination, suggested that while H
2
O
2
 was 
involved in the mechanism of action of these vitamins, the enhanced 
antitumor activity of the vitamin combination was not simply due to an 
excessive increase in H
2
O
2 
production. 
In an initial attempt to elucidate the H
2
O
2
-mediated forces 
underlying these mechanism(s), tumor cells were treated with VC alone, 
VK
3
 alone or with the VC:VK
3
 combination for 1h to allow triggering 
of autoschizis.  Subsequently, the vitamins were removed, culture 
medium was added and changes in thiol levels, lipid peroxidation and 
ATP content were monitored for 5hrs (a time by which most cells 
would be undergoing autoschizis). he efects of continuous vitamin 
exposure over a 5 h time period have already been described in a 
previous manuscript [68]. Since vitamin administration induces H
2
O
2
 
production, the amount of LPO has been evaluated. While the increase 
in lipid peroxidation values for cells were signiicantly higher than 
control levels ater 1hr of vitamin exposure, signiicant levels of lipid 
peroxidation and damage to the cell membrane occur only ater 2–3 
hr vitamin exposure and suggest that wholesale, indiscriminate lipid 
peroxidation was a late event in the cell death process. However, TEM 
micrographs of RT4 cells, that were treated at the same time and dose as 
those employed in this paper, demonstrated that the architecture of the 
mitochondria, lysosomes and endoplasmic reticulum (ER) was rapidly 
altered by vitamin-induced lipid peroxidation and/or disruption 
of the glutathione redox balance in the ER as well as diminution of 
reduced thiols in the membranes of these organelles [20,45,66]. he 
resultant damage to the membranes as well as Ca2+ transport channels 
of the lysosomes, mitochondria and ER membranes leads to increased 
intracellular Ca2+ levels. Ca2+ disregulation also leads to the activation 
of a number of phospholipases, proteases, and DNases [69]. his Ca2+ 
release occurs within the irst 5 minutes of vitamin treatment and 
ultimately leads to cell death [68].
To further diferentiate autoschizis from other types of cell death, 
vitamin-induced changes in ATP levels were determined. While ATP 
levels in sham treated cells remained constant, ATP levels in VK
3
 
treated cells show a steady decline (1.5 fold decrease) during the 5 h. 
VK
3
 has been shown to induce either apoptosis or necrosis depending 
on the dose and duration of exposure [70]. At the dose employed in 
this study (90 µM) VK
3
 would be expected to induce necrosis and 
the diminution of ATP levels is consistent with this expectation. 
Conversely, VC treatment and VC: VK3 treatment led to spikes in 
ATP production. In the case of VC treatment, ATP levels increased 
rapidly in the irst hour and then fell for the next 4hrs.  For the VC:VK
3
 
combination, ATP levels increased 2.3 fold (compared to those of the 
control levels) and then fell to control levels over the next two hours 
which suggests that autoschizis is an active ATP-dependent process. 
VC accumulation in the majority of tumor cells is through GLUT 
transporters in the form of DHA which bio-accumulates and then is 
trapped when it is reduced back to AA which cannot be transported 
through the GLUT transporters. Likewise, VC accumulates in 
mitochondria via GLUT transporters in the same fashion it bio-
accumulated in the cytoplasm [71]. Once inside the mitochondria, 
VC can form a shunt around some of the defective regions of complex 
III of the electron transport chain and thus reconstitute a portion of 
ability to produce ATP that had been lost due to alterations in protein 
complexes in the electron transport chain during oncogenesis [72-74]. 
In the case of the vitamin combination, the doses of both vitamins are 
much lower than those employed with either vitamin alone, i.e. 17-fold 
for VC (8,750 µM / 520 µM) and 17-fold for VK
3
 (90 µM/5.2 µM). Since 
VC is concentrating in the cytoplasm and inside the mitochondria via 
GLUT transporters, one would intuitively expect the higher dose VC 
to produce the threshold dose necessary to form the electron shunt 
before the lower dose VC. hus, the 1h versus the 3h ATP peaks. In 
addition, Elef and co-workers [74] have shown that, when VC and 
VK
3
 in a ratio of 100:1 are administered, menadione accepts electrons 
from coenzyme Q (ubiquinone), shuttles them to ascorbate and then to 
cytochrome c. he shunt was able to bypass the antimycin-a-sensitive 
site in both forward and reversed electron transport; had two intact 
phosphorylation sites; and produced a shit from glycolytic activity to 
increased mitochondrial oxidative phosphorylation and a diminution 
of lactic acidosis. herefore, the combination resulted in a production 
of more ATP than the shunt produced by VC alone. hus, the bigger 
change in ATP production of the vitamin combination compared to 
VC alone. It is believed that the ATP generated by this process allows 
the cells “to commit suicide”.
Conclusion
While VC traditionally is perceived as an antioxidant, it may also 
act as a pro-oxidant, increase DNA damage and induce cell death [75]. 
Vitamin K
3
 is an oxidant that exhibits antitumor activity against a 
variety of tumor cell lines as well as human explants which are resistant 
to other types of chemotherapy [76]. When VC is combined with VK
3
, 
the interaction fosters redox cycling [77] which increases oxidative 
stress. Consequently, the antitumor activity of the vitamins in the 
combination is 12- to 24-fold greater than the individual vitamins for 
the RT-4 cells and 6- to 41-fold greater for the T24 cells.  In previous 
studies with RT4 cells, administration of the vitamin combination 
was shown to induce the rapid production of H
2
O
2
 [70] and ROS 
[45]. Hydrogen peroxide was implicated in the antitumor activity of 
the vitamin combination because addition of exogenous catalase (to 
neutralize the H
2
O
2
) was shown to abrogate their enhanced antitumor 
activity [68]. Within the irst hour following combined vitamin 
treatment, this oxidative stress decreases cellular thiol levels to less 
than half those of sham-treated cells. Previous studies have shown 
that the resulting loss of protection against ROS is accompanied by the 
oxidation and subsequent disruption of cellular caspases (including 
caspase-3) as well as microtubules and other cytoskeletal proteins 
[18,19]. his cytoskeletal disorganization is relected by blister and 
bleb formation as well as by acute distortions in tumor cell shape [20]. 
Because vitamin administration induces H
2
O
2
 production, the amount 
of LPO has been evaluated. While the increase in lipid peroxidation 
values for cells were signiicantly higher than control levels ater 1 hr of 
vitamin exposure, signiicant levels of lipid peroxidation and damage to 
the cell membrane occur only ater 2–3 hr vitamin exposure and suggest 
that wholesale, indiscriminate lipid peroxidation was a late event in the 
cell death process. However, TEM micrographs demonstrated that 
the vitamin combination rapidly altered mitochondrial architecture 
and induced ultrastructural changes in both the smooth and rough 
endoplasmic reticulum (SER, RER) as well. As a consequence of the 
changes, Ca2+ transport systems of the mitochondria, SER and RER 
are perturbed and there is an increase in intracellular Ca2+ levels which 
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leads to the reactivation of DNases [78]. While lipid peroxidation and 
subsequent loss of membrane integrity may be responsible for the 
release of Ca2+ into the cytoplasm, the fact that ATP production by the 
mitochondria increases 1h ater VC treatment and 3h ater combined 
vitamin treatment suggests that the Ca2+ release occurs via modulation 
of the voltage-dependent anion channel (VDAC) [66].  In addition to 
these processes mentioned in this study, a number of cellular processes 
were afected by the presence of AA and especially DHA, including: 
modulation of signal transduction, cell cycle arrest and inhibition of 
glycolytic respiration, inhibition of metastasis [10,26,62,71,79,80]. 
Taken together these results indicate that autoschizis (the type of cell 
death induced by the vitamin combination) entails the coordinated 
modulation of cell signaling and metabolism by VC, VK
3 
in their 
various redox states coupled with the attack of H
2
O
2
 and ROS on 
cellular thiols, membranes, cytoskeleton, and DNA that continues until 
cell death by self-morsellation ensues.
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